Shares of Uniqure NV (NASDAQ:QURE) have been assigned an average recommendation of “Buy” from the fourteen brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $80.00.
A number of analysts recently weighed in on the company. HC Wainwright restated a “buy” rating on shares of Uniqure in a report on Tuesday, September 3rd. Mizuho assumed coverage on Uniqure in a report on Thursday. They issued a “buy” rating and a $67.00 price objective for the company. Zacks Investment Research downgraded Uniqure from a “buy” rating to a “hold” rating in a report on Friday, August 2nd. Janney Montgomery Scott restated a “buy” rating on shares of Uniqure in a report on Tuesday, June 11th. Finally, Chardan Capital restated a “buy” rating on shares of Uniqure in a report on Tuesday, September 3rd.
In other Uniqure news, CEO Matthew C. Kapusta sold 8,000 shares of the stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $71.45, for a total transaction of $571,600.00. Following the completion of the sale, the chief executive officer now directly owns 404,839 shares in the company, valued at approximately $28,925,746.55. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Philip Astley-Sparke sold 6,460 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $60.12, for a total value of $388,375.20. Following the sale, the director now owns 12,406 shares of the company’s stock, valued at $745,848.72. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 30,460 shares of company stock valued at $2,031,415. Company insiders own 2.91% of the company’s stock.
Institutional investors have recently modified their holdings of the business. OMERS ADMINISTRATION Corp acquired a new stake in Uniqure during the 2nd quarter worth about $618,000. FMR LLC grew its holdings in Uniqure by 0.8% during the 1st quarter. FMR LLC now owns 3,688,791 shares of the biotechnology company’s stock worth $220,036,000 after acquiring an additional 29,629 shares during the period. Pearl River Capital LLC acquired a new stake in Uniqure during the 1st quarter worth about $32,000. Vivo Capital LLC acquired a new stake in Uniqure during the 1st quarter worth about $10,757,000. Finally, Harvest Group Wealth Management LLC acquired a new stake in Uniqure during the 1st quarter worth about $26,000. Hedge funds and other institutional investors own 74.70% of the company’s stock.
Shares of QURE traded down $2.15 during trading hours on Friday, reaching $46.41. The stock had a trading volume of 8,331 shares, compared to its average volume of 651,755. Uniqure has a 12 month low of $21.98 and a 12 month high of $82.49. The stock has a market capitalization of $1.77 billion, a PE ratio of -19.83 and a beta of 0.96. The company has a debt-to-equity ratio of 0.51, a quick ratio of 8.07 and a current ratio of 8.07. The company’s 50-day moving average is $55.64 and its two-hundred day moving average is $62.10.
Uniqure (NASDAQ:QURE) last announced its quarterly earnings results on Monday, July 29th. The biotechnology company reported ($0.83) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.75) by ($0.08). Uniqure had a negative net margin of 1,232.30% and a negative return on equity of 61.67%. The firm had revenue of $2.47 million during the quarter, compared to the consensus estimate of $1.53 million. Equities analysts anticipate that Uniqure will post -3.22 earnings per share for the current fiscal year.
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Recommended Story: Technical Analysis of Stocks and What It Means
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.